Premium
Antibody response against NY‐ESO‐1 in CHP‐NY‐ESO‐1 vaccinated patients
Author(s) -
Kawabata Ryohei,
Wada Hisashi,
Isobe Midori,
Saika Takashi,
Sato Shuichiro,
Uenaka Akiko,
Miyata Hiroshi,
Yasuda Takushi,
Doki Yuichiro,
Noguchi Yuji,
Kumon Hiromi,
Tsuji Kazuhide,
Iwatsuki Keiji,
Shiku Hiroshi,
Ritter Gerd,
Murphy Roger,
Hoffman Eric,
Old Lloyd J.,
Monden Morito,
Nakayama Eiichi
Publication year - 2007
Publication title -
international journal of cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.475
H-Index - 234
eISSN - 1097-0215
pISSN - 0020-7136
DOI - 10.1002/ijc.22583
Subject(s) - antibody , immune system , vaccination , antigen , immunology , medicine , epitope , humoral immunity
NY‐ESO‐1 specific humoral responses are frequently observed in patients with various types of NY‐ESO‐1 antigen expressing tumors. In a large proportion of NY‐ESO‐1 antibody‐positive patients of NY‐ESO‐1‐specific CD8 T‐cells can also be detected suggesting that monitoring of the NY‐ESO‐1 specific humoral immune response may be a relevant and more practical surrogate for estimating the overall immune response against NY‐ESO‐1 in clinical vaccine studies. We have immunized 9 cancer patients with full length NY‐ESO‐1 protein formulated with cholesterol‐bearing hydrophobized pullulan (CHP‐NY‐ESO‐1) and investigated the humoral immune responses against NY‐ESO‐1. Seven patients were NY‐ESO‐1 antibody‐negative and 2 patients were positive prior to vaccination. Vaccination with CHP‐NY‐ESO‐1 resulted in the induction or increase of NY‐ESO‐1 antibody responses in all 9 patients immunized. Epitope analysis revealed 5 regions in the NY‐ESO‐1 protein molecule that were recognized by antibodies induced after vaccination. The 5 regions were also recognized by antibodies present in nonvaccinated, NY‐ESO‐1 antibody‐positive cancer patients. A peptide spanning amino acids 91–108 was recognized in 6 out of 9 vaccinated patients and in 8 out of 9 nonvaccinated, sero‐positive patients, being the most dominant antigenic epitope in NY‐ESO‐1 for antibody recognition in cancer patients. In conclusion, we showed that CHP‐NY‐ESO‐1 protein vaccination had a potent activity for inducing humoral immune responses against NY‐ESO‐1 antigen in cancer patients. The antigenic epitopes recognized by antibodies in the vaccinated patients were similar to those recognized in cancer patients with spontaneous humoral immunity against NY‐ESO‐1. © 2007 Wiley‐Liss, Inc.